Boston Common Asset Management, LLC Abb Vie Inc. Transaction History

Boston Common Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 26, 2023	BUY	$138.31 - $165.87 $21,161 - $25,378	153 Added 2.48%	6,333 $1.02 Million
Q3 2022 Oct 20, 2022	BUY	$134.21 - $153.93 $13,555 - $15,546	101 Added 1.66%	6,180 $829,000
Q2 2022 Aug 10, 2022	BUY	$137.62 - $174.96 $73,489 - $93,428	534 Added 9.63%	6,079 $931,000
Q1 2022 May 16, 2022	SELL	$131.98 - $163.75 $87,502 - $108,566	-663 Reduced 10.68%	5,545 $898,000
Q4 2021 Jan 31, 2022	BUY	$107.43 - $135.93 $36,096 - $45,672	336 Added 5.72%	6,208 $840,000
Q3 2021 Nov 12, 2021	BUY	$106.4 - $120.78 $4,149 - $4,710	39 Added 0.67%	5,872 $633,000
Q2 2021 Aug 19, 2021	BUY	$105.21 - $117.21 $42,084 - $46,884	400 Added 7.36%	5,833 $657,000
Q1 2021 May 14, 2021	BUY	$102.3 - $112.62 $5,217 - $5,743	51 Added 0.95%	5,433 $587,000
Q4 2020 Feb 05, 2021	BUY	$80.49 - $108.67 $433,197 - $584,861	5,382 New	5,382 $577,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boston Common Asset Management, LLC with notifications on news.